|
Characteristics
|
(n = 24)
|
|---|
|
Age at onset, years
|
39.8 ± 12.3
|
|
Female gender, n (%)
|
5 (21%)
|
|
Hypertension, n (%)
|
6 (25%)
|
|
Diabetes mellitus, n (%)
|
2 (8%)
|
|
Smoking
|
6 (25%)
|
|
Alcohol
|
4 (17%)
|
|
Cholesterol, mmol/L
|
4.7 ± 1.6
|
|
LDL-c, mmol/L
|
3.2 ± 1.1
|
|
NT-proBNP, pg/mL
|
2057.5 (698,18,381)
|
|
NYHA III or IV, n(%)
|
21 (87.5%)
|
|
ICD, n (%)
|
2 (8%)
|
|
Atrial fibrillation
|
2 (8%)
|
|
Complete RBBB/LBBB
|
1 (4%)
|
|
LVEF, %
|
27.0 ± 9.9
|
|
LVEDD, mm
|
70.1 ± 7.8
|
|
LA diameter, mm
|
49.4 ± 9.6
|
|
ACEI/ARB/ARNI, n (%)
|
18 (75%)
|
|
Beta-blockers, n (%)
|
21 (87.5%)
|
|
Spironolactone, n (%)
|
22 (91.7%)
|
|
Diuretics, n (%)
|
21 (87.5%)
|
- All variables are given as either number present (% of total number) or mean ± SD, except for NT-proBNP (N-terminal B-type natriuretic peptide), which is given as mean and range
- NYHA, New York Heart Association functional classification; ICD, implantable cardioverter defibrillator; RBBB/LBBB, right bundle branch block/left bundle branch block; LVEDD, left ventricular end-diastolic dimension; LA, left atrium; ACEI/ARB/ARNI, angiotensin converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor
